| Ziad Kanaan, MD | |
|
18100 Oakwood Blvd Ste 205, Dearborn, MI 48124-4085 | |
| (313) 438-7880 | |
| (313) 438-7882 |
| Full Name | Ziad Kanaan |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Gastroenterology |
| Location | 18100 Oakwood Blvd Ste 205, Dearborn, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245598606 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 4301101616 (Michigan) | Primary |
| Entity Name | Ella E M Brown Charitable Circle |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366591794 PECOS PAC ID: 1254228745 Enrollment ID: O20040616001008 |
News Archive
This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.
Professional athletes undergoing treatment for cancer often are in the headlines.
Use of a common antibiotic may be undercutting its utility as a first-line defense against drug-resistant tuberculosis (TB). Fluoroquinolones are the most commonly prescribed class of antibiotics in the U.S. and are used to fight a number of different infections such as sinusitis and pneumonia. They are also an effective first line of defense against TB infections that show drug resistance. New research shows, however, that widespread general use of fluoroquinolones may be creating a strain of fluoroquinolone-resistant TB.
This protection is provided by a human protein, Elafin, which is artificially introduced into dairy produce bacteria (Lactococcus lactis and Lactobacillus casei). In time, this discovery could be useful for individuals suffering from chronic inflammatory diseases such as Crohn's disease or ulcerative colitis.
› Verified 5 days ago
| Entity Name | University Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447299797 PECOS PAC ID: 8628087681 Enrollment ID: O20060419000518 |
News Archive
This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.
Professional athletes undergoing treatment for cancer often are in the headlines.
Use of a common antibiotic may be undercutting its utility as a first-line defense against drug-resistant tuberculosis (TB). Fluoroquinolones are the most commonly prescribed class of antibiotics in the U.S. and are used to fight a number of different infections such as sinusitis and pneumonia. They are also an effective first line of defense against TB infections that show drug resistance. New research shows, however, that widespread general use of fluoroquinolones may be creating a strain of fluoroquinolone-resistant TB.
This protection is provided by a human protein, Elafin, which is artificially introduced into dairy produce bacteria (Lactococcus lactis and Lactobacillus casei). In time, this discovery could be useful for individuals suffering from chronic inflammatory diseases such as Crohn's disease or ulcerative colitis.
› Verified 5 days ago
| Entity Name | Michigan Healthcare Professionals Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295023547 PECOS PAC ID: 0345413258 Enrollment ID: O20111109000027 |
News Archive
This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.
Professional athletes undergoing treatment for cancer often are in the headlines.
Use of a common antibiotic may be undercutting its utility as a first-line defense against drug-resistant tuberculosis (TB). Fluoroquinolones are the most commonly prescribed class of antibiotics in the U.S. and are used to fight a number of different infections such as sinusitis and pneumonia. They are also an effective first line of defense against TB infections that show drug resistance. New research shows, however, that widespread general use of fluoroquinolones may be creating a strain of fluoroquinolone-resistant TB.
This protection is provided by a human protein, Elafin, which is artificially introduced into dairy produce bacteria (Lactococcus lactis and Lactobacillus casei). In time, this discovery could be useful for individuals suffering from chronic inflammatory diseases such as Crohn's disease or ulcerative colitis.
› Verified 5 days ago
| Entity Name | Beaumont Medical Group- Specialty Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578072906 PECOS PAC ID: 7214299866 Enrollment ID: O20180320002549 |
News Archive
This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.
Professional athletes undergoing treatment for cancer often are in the headlines.
Use of a common antibiotic may be undercutting its utility as a first-line defense against drug-resistant tuberculosis (TB). Fluoroquinolones are the most commonly prescribed class of antibiotics in the U.S. and are used to fight a number of different infections such as sinusitis and pneumonia. They are also an effective first line of defense against TB infections that show drug resistance. New research shows, however, that widespread general use of fluoroquinolones may be creating a strain of fluoroquinolone-resistant TB.
This protection is provided by a human protein, Elafin, which is artificially introduced into dairy produce bacteria (Lactococcus lactis and Lactobacillus casei). In time, this discovery could be useful for individuals suffering from chronic inflammatory diseases such as Crohn's disease or ulcerative colitis.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ziad Kanaan, MD 26901 Beaumont Blvd Ste 3d, Southfield, MI 48033-3849 Ph: () - | Ziad Kanaan, MD 18100 Oakwood Blvd Ste 205, Dearborn, MI 48124-4085 Ph: (313) 438-7880 |
News Archive
This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.
Professional athletes undergoing treatment for cancer often are in the headlines.
Use of a common antibiotic may be undercutting its utility as a first-line defense against drug-resistant tuberculosis (TB). Fluoroquinolones are the most commonly prescribed class of antibiotics in the U.S. and are used to fight a number of different infections such as sinusitis and pneumonia. They are also an effective first line of defense against TB infections that show drug resistance. New research shows, however, that widespread general use of fluoroquinolones may be creating a strain of fluoroquinolone-resistant TB.
This protection is provided by a human protein, Elafin, which is artificially introduced into dairy produce bacteria (Lactococcus lactis and Lactobacillus casei). In time, this discovery could be useful for individuals suffering from chronic inflammatory diseases such as Crohn's disease or ulcerative colitis.
› Verified 5 days ago
Albagir Mohamed Alarabi, M.D Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 18101 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-593-7000 | |
Dr. Rama V Thyagarajan, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 18181 Oakwood Blvd Ste 101, Medical Office Building, Dearborn, MI 48124 Phone: 313-436-2426 Fax: 313-436-2440 | |
Adeeb M Atassi, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 18181 Oakwood Blvd, Suite Number 208, Dearborn, MI 48124 Phone: 313-563-3332 | |
Mihaela A. Lupu, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 18181 Oakwood Blvd, Ste 208, Dearborn, MI 48124 Phone: 313-271-5670 Fax: 313-271-1053 | |
Violet Asfour, Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 18100 Oakwood Blvd, Dearborn, MI 48124 Phone: 313-436-2578 | |
Raed Haddad, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9720 Dix, Ste B, Dearborn, MI 48120 Phone: 313-843-1973 Fax: 313-843-1961 | |
Dr. Denise Kirsch, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 18101 Oakwood Blvd Ste 101, Dearborn, MI 48124 Phone: 313-436-2426 Fax: 313-436-2440 |